Kirk Seward
Principal investigator, leads MERCATOR MEDSYSTEMS, INC..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$6.0MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $6.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 11, 2026 | NIH | SBIR Phase II Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1.0M | MERCATOR MEDSYSTEMS, INC. |
| Aug 4, 2025 | NIH | SBIR Phase II Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $1.1M | MERCATOR MEDSYSTEMS, INC. |
| Mar 7, 2025 | NIH | SBIR Phase II Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1.0M | MERCATOR MEDSYSTEMS, INC. |
| Sep 18, 2024 | NIH | SBIR Phase II Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $1.6M | MERCATOR MEDSYSTEMS, INC. |
| Dec 29, 2023 | NIH | SBIR Phase II Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1.0M | MERCATOR MEDSYSTEMS, INC. |
| Sep 20, 2021 | NIH | STTR Phase I Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $300K | MERCATOR MEDSYSTEMS, INC. with MASSACHUSETTS GENERAL HOSPITAL |
Peer ranks
Federal funding#209
Awards as PI#349
Patents#505
Companies
- MERCATOR MEDSYSTEMS, INC.Leads (SEC Form D) · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.